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c o r e t v a s a 5 6 ( 2 0 1 4 ) e 4 9 4 – e 5 1 8e496Table 2 – Levels of evidence.
Level of 
evidence A 
Data  deri ved  from mul tiple  randomi zed 
clinical  tri als  or  meta- analyses. 
Level of 
evidence B 
Data  derived  from a  single  randomized 




Consensus  of opinion  of  the exp erts 
and/or  small  studies,  retrospective 
stud ies,  registries.The 2013 ESH/ESC Guidelines adhere to the following
fundamental principles: (i) to base recommendations on
properly conducted studies, (ii) to consider, as the highest
priority, data from randomized, controlled trials (RCTs)
and their meta-analyses, and (iii) to grade the level of
scientiﬁc evidence and the strength of recommendations
(Tables 1 and 2).
1. Epidemiological aspects
The prevalence of hypertension appears to be around 30–45%
of the general population, with a steep increase with ageing.
Ofﬁce BP bears an independent continuous relationship with
the incidence of several CV events (stroke, myocardial
infarction, sudden death, heart failure and PAD) and of ESRD.
This is true at all ages and in all ethnic groups. The relationship
with BP extends from high BP levels to relatively low values of
110–115 mmHg for SBP and 70–75 mmHg for diastolic BP (DBP).
SBP appears to be a better predictor of events than DBP afterTable 1 – Classes of recommendations.
Classes  of 
recommend ation s
eneg ro/dna ecnedivE I ssalC
that a given  treatm
Class  II 
divergence  of  opinio
treatment  or  proce
    Class  IIa Weight  of evi dence
    Class IIb
established  by e vide
Class  III  Evi dence  or  genera
the  given  treatmen
is not  useful/effe cti
cases  may  be  harmfthe age of 50 years, and in elderly individuals pulse pressure
has a possible additional prognostic role.
1.1. Deﬁnition and classiﬁcation of hypertension
The recommended classiﬁcation is unchanged from previous
guidelines (Table 3). Hypertension is deﬁned as values
≥140 mmHg SBP and/or ≥90 mmHg DBP. The same classiﬁcationSuggested w ording  to 
use
 tnemeerga lar
ent  or  procedure 
Is  recomm ended /is 
indicated
n  about  the 
dure. 
/opinion  is  in Should be consid ered
nce/opinion. 
May  be consid ered
l  agreement  that 
t  or  procedure 
ve,  and  in  some 
ul. 
Is not  rec ommende d
Table 3 – Definitions and classification of office blood
pressure levels (mmHg).a
Category Systolic Diastolic
Optimal <120 and <80
Normal 120–129 and/or 80–84
High normal 130–139 and/or 85–89
Grade 1 hypertension 140–159 and/or 90–99
Grade 2 hypertension 160–179 and/or 100–109
Grade 3 hypertension ≥180 and/or ≥110
Isolated systolic hypertension ≥140 and <90
a The blood pressure (BP) category is defined by the highest level of
BP, whether systolic or diastolic. Isolated systolic hypertension
should be graded 1, 2, or 3 according to systolic BP values in the
ranges indicated.
c o r e t v a s a 5 6 ( 2 0 1 4 ) e 4 9 4 – e 5 1 8 e497is used in young, middle-aged and elderly subjects, whereas
different criteria, based on percentiles, are adopted in children
and teenagers.Table 4 – Factors—other than office BP—influencing prognosis;
Risk factors
Male sex
Age (men ≥55 years; women ≥65 years)
Smoking
Dyslipidaemia
Total cholesterol >4.9 mmol/L (190 mg/dL), and/or
Low-density lipoprotein cholesterol >3.0 mmol/L (115 mg/dL), and/or
High-density lipoprotein cholesterol: men <1.0 mmol/L (40 mg/dL), w
Triglycerides >1.7 mmol/L (150 mg/dL)
Fasting plasma glucose 5.6–6.9 mmol/L (102–125 mg/dL)
Abnormal glucose tolerance test
Obesity [BMI ≥30 kg/m2 (height2)]
Abdominal obesity (waist circumference: men ≥102 cm; women ≥88 cm
Family history of premature CVD (men aged <55 years; women aged <
Asymptomatic organ damage
Pulse pressure (in the elderly) ≥60 mmHg
Electrocardiographic LVH (Sokolow–Lyon index >3.5 mV; RaVL >1.1 mV
Echocardiographic LVH [LVM index: men >115 g/m2; women >95 g/m2
Carotid wall thickening (IMT >0.9 mm) or plaque
Carotid–femoral PWV >10 m/s
Ankle–brachial index <0.9
CKD with eGFR 30–60 mL/min/1.73 m2 (BSA)
Microalbuminuria (30–300 mg/24 h), or albumin–creatinine ratio (30–30
Diabetes mellitus
Fasting plasma glucose ≥7.0 mmol/L (126 mg/dL) on two repeated mea
HbA1c >7% (53 mmol/mol), and/or
Post-load plasma glucose >11.0 mmol/L (198 mg/dL)
Established CV or renal disease
Cerebrovascular disease: ischaemic stroke; cerebral haemorrhage; tran
CHD: myocardial infarction; angina; myocardial revascularization with
Heart failure, including heart failure with preserved EF
Symptomatic lower extremities peripheral artery disease
CKD with eGFR <30 mL/min/l.73m2 (BSA); proteinuria (>300 mg/24 h)
Advanced retinopathy: haemorrhages or exudates, papilloedema
BMI, body mass index; BP, blood pressure; BSA, body surface area; CAB
chronic kidney disease; CV, cardiovascular; CVD, cardiovascular disease; E
glycated haemoglobin; IMT, intima media thickness; LVH, left ventricular
intervention; PWV, pulse wave velocity.
a Risk maximal for concentric LVH: increased LVM index with a wall thi1.2. Hypertension and total cardiovascular risk
Prevention of CHD should be related to quantiﬁcation of total
CV risk. For this purpose, The Systematic COronary Risk
Evaluation (SCORE) model has been developed based on large
European cohort studies. The model estimates the risk of
dying from CV disease over 10 years based on age, gender,
smoking habits, total cholesterol and SBP; other factors
inﬂuence prognosis as well (Table 4).
In young patients, absolute total CV risk can be low even in
the presence of high BP with additional risk factors. If
insufﬁciently treated, however, this condition may lead to a
partly irreversible high-risk condition years later. In younger
subjects, treatment decisions on hypertension should better
be guided by quantiﬁcation of relative rather than absolute
risk.
The classiﬁcation in low, moderate, high and very high risk
is retained in the current guidelines (Fig. 1). used for stratification of total CV risk in Fig. 1.
omen <1.2 mmol/L (46 mg/dL), and/or
) (in Caucasians)
65 years)
; Cornell voltage duration product >244 mV ms), or
(BSA)]a
0 mg/g; 3.4–34 mg/mmol) (preferentially on morning spot urine)
surements, and/or
sient ischaemic attack
 PCI or CABG
G, coronary artery bypass graft; CHD, coronary heart disease; CKD,
F, ejection fraction; eGFR, estimated glomerular ﬁltration rate; HbA1c,
 hypertrophy; LVM, left ventricular mass; PCI, percutaneous coronary
ckness/radius ratio of >0.42.
Total cardiovascular risk assessment.
Recommendations Classa Levelb
In asymptomatic subjects 
with hypertension but free 
of CVD, CKD, and diabetes, 
using the SCORE model is 
recommended as a minimal 
requirement.
I B
As there is evidence that
OD predicts CV death
independently of SCORE,
a search for OD should be
considered , particularly in
individuals at moderate risk.    
IIa B
It is recommended that 
decisions on treatment 
strategies depend on the initial 
level of total CV risk.
I B
CKD, chronic kidney disease; CV, cardiovascular; CVD, cardiovas-




c o r e t v a s a 5 6 ( 2 0 1 4 ) e 4 9 4 – e 5 1 8e4982. Diagnostic evaluation
The initial evaluation of a patient with hypertension should (i)
conﬁrm the diagnosis of hypertension, (ii) detect causes of
secondary hypertension, and (iii) assess CV risk, OD and
concomitant clinical conditions.Fig. 1 – Stratification of total CV risk in categories of low, modera
prevalence of RFs, asymptomatic OD, diabetes, CKD stage or symp
out-of-office BP (masked hypertension) have a CV risk in the hyper
of-office BP (white-coat hypertension), particularly if there is no d
hypertension for the same office BP. BP, blood pressure; CKD, chro
disease; DBP, diastolic blood pressure; HT, hypertension; OD, org2.1. Blood pressure measurement
2.1.1. Ofﬁce blood pressure
The principles of its measurement are summarized in
Table 5.
2.1.2. Out-of-ofﬁce BP
It is commonly assessed by ABPM or HBPM. These two
methods provide somewhat different information and they
should be regarded as complementary, rather than alterna-
tive. The correspondence between them is fair to moderate.
Cut-off values for the deﬁnition of hypertension and clinical
indications for home and ambulatory BP are reported in
Tables 6 and 7.
ABPM is performed with the patient wearing a portable BP
measuring device, usually on the non-dominant arm, for a
24–25 h period. At the time of ﬁtting of the portable device, the
difference between the initial values and those from BP
measurement by the operator should not be greater than
5 mmHg. At least 70% of BPs during daytime and nighttime
periods should be satisfactory.
BP normally decreases during the night. Categories accord-
ing to nocturnal BP fall have been proposed: nocturnal BP
increase (night–day BP ratio >1.0); mild dipping (0.9 <ratio
≤1.0); dipping (0.8 <ratio ≤0.9); and extreme dipping (ratio ≤0.8).
The reproducibility of the dipping pattern is, however, limited.
Possible reasons for absence of dipping are sleep disturbance,
obstructive sleep apnoea, obesity, high salt intake in salt-
sensitive subjects, orthostatic hypotension, autonomic dys-
function, chronic kidney disease (CKD), diabetic neuropathy
and old age.
24-h average BP has been consistently shown to have a
stronger relationship with morbid or fatal events than ofﬁcete, high and very high risk according to SBP and DBP and
tomatic CVD. Subjects with a high normal office but a raised
tension range. Subjects with a high office BP but normal out-
iabetes, OD, CVD or CKD, have lower risk than sustained
nic kidney disease; CV, cardiovascular; CVD, cardiovascular
an damage; RF, risk factor; SBP, systolic blood pressure.
Table 5 – Office blood pressure measurement.
When measuring BP in the ofﬁce, care should be taken:
 To allow the patients to sit for 3–5 min before beginning BP measurements.
 To take at least two BP measurements, in the sitting position, spaced 1–2 min apart, and additional measurements if the ﬁrst two are
quite different. Consider the average BP if deemed appropriate.
 To take repeated measurements of BP to improve accuracy in patients with arrhythmias, such as atrial ﬁbrillation.
 To use a standard bladder (12–13 cm wide and 35 cm long), but have a larger and a smaller bladder available for large (arm circumference
>32 cm) and thin arms, respectively.
 To have the cuff at the heart level, whatever the position of the patient.
 When adopting the auscultatory method, use phase I and V (disappearance) Korotkoff sounds to identify systolic and diastolic BP,
respectively.
 To measure BP in both arms at ﬁrst visit to detect possible differences. In this instance, take the arm with the higher value as the
reference.
 To measure at the ﬁrst visit, BP 1 and 3 min after assumption of the standing position in elderly subjects, diabetic patients, and in other
conditions in which orthostatic hypotension may be frequent or suspected.
 To measure, in case of conventional BP measurement, heart rate by pulse palpation (at least 30 s) after the second measurement in the
sitting position.
BP, blood pressure.
Table 6 – Definitions of hypertension by office and out-of-





Ofﬁce BP ≥140 and/or ≥90
Ambulatory BP
Daytime (or awake) ≥135 and/or ≥85
Nighttime (or asleep) ≥120 and/or ≥70
24-h ≥130 and/or ≥80
Home BP ≥135 and/or ≥85
BP, blood pressure.
Table 7 – Clinical indications for out-of-office blood
pressure measurement for diagnostic purposes.
Clinical indications for HBPM or ABPM
 Suspicion of white-coat hypertension
- Grade I hypertension in the ofﬁce
- High ofﬁce BP in individuals without asymptomatic organ
damage and at low total CV risk
 Suspicion of masked hypertension
- High normal BP in the ofﬁce
- Normal ofﬁce BP in individuals with asymptomatic organ
damage or at high total CV risk
 Identiﬁcation of white-coat effect in hypertensive patients
 Considerable variability of ofﬁce BP over the same or different
visits
 Autonomic, postural, post-prandial, siesta- and drug-induced
hypotension
 Elevated ofﬁce BP or suspected pre-eclampsia in pregnant
women
 Identiﬁcation of true and false resistant hypertension
Speciﬁc indications for ABPM
 Marked discordance between ofﬁce BP and home BP
 Assessment of dipping status
 Suspicion of nocturnal hypertension or absence of dipping,
such as in patients with sleep apnoea, CKD, or diabetes
 Assessment of BP variability
ABPM, ambulatory blood pressure monitoring; BP, blood pressure;
CKD, chronic kidney disease; CV, cardiovascular; HBPM, home
blood pressure monitoring.
c o r e t v a s a 5 6 ( 2 0 1 4 ) e 4 9 4 – e 5 1 8 e499BP. Nighttime BP is a stronger predictor than daytime BP. The
incidence of CV events is higher in patients with a lesser drop
in nocturnal BP. Extreme dippers may have an increased risk
for stroke.
Home BP should be measured daily on at least 3–4 days and
preferably on 7 consecutive days; in the mornings as well as in
the evenings. BP is measured in a quiet room, with the patient
in the seated position, back and arm supported, after 5 min of
rest and with two measurements per occasion taken 1–2 min
apart. The prognostic signiﬁcance of home BP is similar to that
of ambulatory BP.
Out-of-ofﬁce BP is an important adjunct to conventional
ofﬁce BP measurement, but the latter currently remains the
'gold standard' for management of hypertension. For initial
assessment of the patient, HBPM may be more suitable in
primary care and ABPM in specialist care.
2.1.3. White-coat (or isolated ofﬁce) hypertension and masked
(or isolated ambulatory) hypertension
WCH refers to thecondition inwhich BP iselevated intheofﬁce at
repeated visits and normal out of the ofﬁce, either on ABPM or
HBPM. Conversely, BP may be normal in the ofﬁce and
abnormally high out of the medical environment, which is
termed 'masked hypertension'. There is only moderate agree-
ment between the deﬁnition of WCH (or masked hypertension)
diagnosed by ABPM or HBPM. The terms 'WCH' and 'masked
hypertension' should be reserved to deﬁne untreated individua-
ls.
The prevalence of WCH is about 32% among hypertensive
subjects (55% in grade 1 hypertension and to only about 10% in
grade 3 hypertension). Factors related to increased prevalence
of WCH are: age, female sex and non-smoking. The long-term
CV risk of this condition is probably intermediate between
sustained hypertension and true normotension. The diagnosis
of WCH should be conﬁrmed within 3–6 months and these
patients must be followed-up closely.
The prevalence of masked hypertension averages about
13% in population-based studies. Several factors may raise
out-of-ofﬁce BP relative to ofﬁce BP, such as younger age, male
Table 8 – Personal and family medical history.
1. Duration and previous level of high BP, including measurements at home
2. Secondary hypertension
a) Family history of CKD (polycystic kidney).
b) History of renal disease, urinary tract infection, haematuria, analgesic abuse (parenchymal renal disease).
c) Drug/substance intake, e.g. oral contraceptives, liquorice, carbenoxolone, vasoconstrictive nasal drops, cocaine, amphetamines,
gluco- and mineralocorticosteroids, non-steroidal anti-inﬂammatory drugs, erythropoietin, cyclosporine.
d) Repetitive episodes of sweating, headache, anxiety, palpitations (pheochromocytoma).
e) Episodes of muscle weakness and tetany (hyperaldosteronism).
f) Symptoms suggestive of thyroid disease.
3. Risk factors
a) Family and personal history of hypertension and CVD
b) Family and personal history of dyslipidaemia.
c) Family and personal history of diabetes mellitus (medications, blood-glucose levels, polyuria).
d) Smoking habits.
e) Dietary habits.
f) Recent weight changes; obesity.
g) Amount of physical exercise.
h) Snoring; sleep apnoea (information also from partner).
i) Low birth-weight.
4. History and symptoms of organ damage and cardiovascular disease
a) Brain and eyes: headache, vertigo, impaired vision, TIA, sensory or motor deﬁcit, stroke, carotid revascularization.
b) Heart: chest pain, shortness of breath, swollen ankles, myocardial infarction, revascularization, syncope, history of palpitations,
arrhythmias, especially atrial ﬁbrillation.
c) Kidney: thirst, polyuria, nocturia, haematuria.
d) Peripheral arteries: cold extremities, intermittent claudication, pain-free walking distance, peripheral revascularization.
e) History of snoring/chronic lung disease/sleep apnoea.
f) Cognitive dysfunction.
5. Hypertension management
a) Current antihypertensive medication.
b) Past antihypertensive medication.
c) Evidence of adherence or lack of adherence to therapy.
d) Efﬁcacy and adverse effects of drugs.
BP, blood pressure; CKD, chronic kidney disease; CVD, cardiovascular disease; TIA, transient ischaemic attack.
c o r e t v a s a 5 6 ( 2 0 1 4 ) e 4 9 4 – e 5 1 8e500gender, smoking, alcohol consumption, physical activity,
exercise-induced hypertension, anxiety, job stress, obesity,
diabetes, CKD and family history of hypertension. The
prevalence is higher when ofﬁce BP is in the high normalTable 9 – Physical examination for secondary hypertension, or
Signs suggesting secondary hypertension
 Features of Cushing syndrome.
 Skin stigmata of neuroﬁbromatosis (pheochromocytoma).
 Palpation of enlarged kidneys (polycystic kidney).
 Auscultation of abdominal murmurs (renovascular hypertension).
 Auscultation of precordial or chest murmurs (aortic coarctation; aort
 Diminished and delayed femoral pulses and reduced femoral blood p
aortic disease; lower extremity artery disease).
 Left-right arm BP difference (aortic coarctation; subclavian artery ste
Signs of organ damage
 Brain: motor or sensory defects.
 Retina: fundoscopic abnormalities.
 Heart: heart rate, 3rd or 4th heart sound, heart murmurs, arrhythmi
 Peripheral arteries: absence, reduction, or asymmetry of pulses, cold
 Carotid arteries: systolic murmurs.
Evidence of obesity
 Weight and height.
 Calculate BMI: body weight/height2 (kg/m2).
 Waist circumference measured in the standing position, at a level m
rib) and uppermost border of the iliac crest.
BP, blood pressure; BMI, body mass index.range. The incidence of CV events is similar to the incidence in
sustained hypertension. The fact that masked hypertension is
largely undetected and untreated may have contributed to this
ﬁnding.gan damage and obesity.
ic disease; upper extremity artery disease).
ressure compared to simultaneous arm BP (aortic coarctation;
nosis).
as, location of apical impulse, pulmonary rales, peripheral oedema.
 extremities, ischaemic skin lesions.
idway between the lower border of the costal margin (the lowest
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The additive predictive value of central BP beyond brachial BP
was either marginal or not statistically signiﬁcant in most
studies. Thus, although the measurement of central is of great
interest for analyses in pathophysiology and pharmacology,
more investigation is needed before recommending their
routine clinical use. The only exception may be isolated
systolic hypertension in the young; in some of these
individuals increased SBP at the brachial level may be due
to high ampliﬁcation of the central pressure wave, while




See Table 9.Blood pressure management, history, and physical ex-
amination.
Recommendations Classa Levelb
It is recommended to obtain a
comprehensive medical history and
physical examination in all patients with
hypertension to verify the diagnosis,
detect causes of secondary hypertension,
record CV risk factors, and to identify
OD and other CVDs.
I C
Obtaining a family histo ry is
recommended to i nvestigate familial
predisposition to  hype rtension and
CVDs.
Office BP is recommended for screening
and diagnosis of hypertension.
I B
I B
It is recommended that the diagnosis of
hype rtension be based on at least t wo BP
measurements per visit and on at least
two visits. 
I C
It is recommended that all  hype rtensi ve
patients undergo palpation of the pulse
at rest to determine hea rt rate and to
search for arrhythmias, especially atrial
fibrillation. 
Out-of-office BP should be considered
to confirm the diagnosis of hypertension,
identify the type of hypertension, detect
hypotensive episodes, and maximize
prediction of CV risk.
For out-of-office BP measurements, ABPM
or HBPM may be considered depending
on indicaton, availability, ease, cost of use




ABPM, ambulatory blood pressure monitoring; BP, blood pressure;
CV, cardiovascular; CVD, cardiovascular disease; HBPM, home
blood pressure monitoring; OD, organ damage.
aClass of recommendation.
bLevel of evidence.2.4. Laboratory investigations
Laboratory investigations should progress from the most
simple to the more complicated ones (Table 10).
2.5. Asymptomatic organ damage
2.5.1. Heart
A 12-lead ECG should be part of the routine assessment of all
hypertensive patients. Its sensitivity in detecting LVH is low.
Atrial ﬁbrillation is a very frequent and common cause of CV
complications, especially stroke, in hypertensive patients.
Echocardiography is more sensitive in diagnosing LVH and
is useful to reﬁne CV and renal risk. Hypertension is associated
with alterations of LV relaxation and ﬁlling. Hypertension-
induced diastolic dysfunction is associated with concentric
geometry. Determination of left atrial dilatation can provide
additional information and is a prerequisite for the diagnosis
of diastolic dysfunction. Normal ranges and cut-off values for
hypertensive heart disease for key echocardiographic param-
eters are summarized in Table 11. The use of echocardiogra-
phy depends on availability and cost.
2.5.2. Blood vessels
Ultrasound examination of the carotid arteries with measure-
ment of intima media thickness and/or the presence of
plaques has been shown to predict both stroke and myocardial
infarction, independently of traditional CV risk factors. The
added predictive value is primarily found in asymptomatic
individuals at intermediate CV risk.
Carotid–femoral PWV is the 'gold standard' for measuring
aortic stiffness. A recent expert consensus statement adjusted
this threshold value to 10 m/s, by using the direct carotid-to-
femoral distance multiplied by 0.8. The additive value of PWV
above and beyond traditional risk factors has been quantiﬁed
in a number of studies. A substantial proportion of patients at
intermediate risk could be reclassiﬁed into a higher or lower
CV risk, when arterial stiffness is measured.
A low ankle–brachial index (i.e. <0.9) signals PAD and has
predictive value for CV events. It is useful for detecting PAD
especially in individuals with a high likelihood of PAD.
2.5.3. Kidney
The diagnosis of hypertension-induced renal damage is based
on reduced eGFR and/or on albuminuria. Microalbuminuria
has been shown to predict the development of diabetic
nephropathy, while the presence of overt proteinuria generally
indicates the existence of established renal parenchymatous
disease. The ﬁnding of an impaired renal function in a
hypertensive patient constitutes a very potent and frequent
predictor of future CV events and death.
2.5.4. Fundoscopy
Grade III (retinal haemorrhages, microaneurysms, hard
exudates, and cotton wool spots) and grade IV retinopathy
(grade III signs and papilloedema and/or macular oedema) are
indicative of severe hypertensive retinopathy, with a high
predictive value for mortality. Criticism with respect to the
reproducibility of grade I and grade II retinopathy has been
raised.
Table 10 – Laboratory investigations.
Routine tests
 Haemoglobin and/or haematocrit.
 Fasting plasma glucose.
 Serum total cholesterol, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol.
 Fasting serum triglycerides.
 Serum potassium and sodium.
 Serum uric acid.
 Serum creatinine (with estimation of GFR).
 Urine analysis: microscopic examination; urinary protein by dipstick test; test for microalbuminuria.
 12-Lead ECG.
Additional tests, based on history, physical examination, and ﬁndings from routine laboratory tests
 Haemoglobin A1c (if fasting plasma glucose is >5.6 mmol/L (102 mg/dL) or previous diagnosis of diabetes).
 Quantitative proteinuria (if dipstick test is positive); urinary potassium and sodium concentration and their ratio.
 Home and 24-h ambulatory BP monitoring.
 Echocardiogram.
 Holter monitoring in case of arrhythmias.
 Carotid ultrasound.
 Peripheral artery/abdominal ultrasound.
 Pulse wave velocity.
 Ankle–brachial index.
 Fundoscopy.
Extended evaluation (mostly domain of the specialist)
 Further search for cerebral, cardiac, renal, and vascular damage, mandatory in resistant and complicated hypertension.
 Search for secondary hypertension when suggested by history, physical examination, or routine and additional tests.
BP, blood pressure; ECG, electrocardiogram; GFR, glomerular ﬁltration rate.
Table 11 – Cut-off values for parameters used in the
assessment of LV remodelling and diastolic function in
patients with hypertension. Based on Lang et al. and
Nagueh et al.
Parameter Abnormal if
LV mass index (g/m2) >95 (women)
>115 (men)
Relative wall thickness (RWT) >0.42
Diastolic function
Septal e0 velocity (cm/s) <8
Lateral e0 velocity (cm/s) <10
LA volume index (mL/m2) ≥34
LV ﬁlling pressures
E/e0 (averaged) ratio ≥13
LA, left atrium; LV, left ventricle; RWT, relative wall thickness.
Table 12 – Predictive value, availability, reproducibility and cos
Marker Cardiovascular predicti
Electrocardiography +++ 
Echocardiography, plus Doppler ++++ 
Estimated glomerular ﬁltration rate +++ 
Microalbuminuria +++ 
Carotid intima media thickness and plaque +++ 
Arterial stiffness (pulse wave velocity) +++ 
Ankle–brachial index +++ 
Fundoscopy +++ 
Additional measurements
Coronary calcium score ++ 
Endothelial dysfunction ++ 
Cerebral lacunae/white matter lesions ++ 
Cardiac magnetic resonance ++ 
Scores are from + to ++++.
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Hypertension is, beyond stroke, also associated with the risk
of asymptomatic brain damage noticed on cerebral MRI.
White matter hyperintensities can be seen in almost all
elderly individuals with hypertension; silent infarcts are
found in 10–30% of patients. Another type of lesion is
microbleeds, seen in about 5% of individuals. White matter
hyperintensities and silent infarcts are associated with stroke
and cognitive decline. Brain damage should be sought in all
hypertensive patients with neural disturbance and memory
loss. Suitable cognitive evaluation tests may be used in elderly
hypertensive patients.t-effectiveness of some markers of organ damage.













c o r e t v a s a 5 6 ( 2 0 1 4 ) e 4 9 4 – e 5 1 8 e503Table 12 summarizes the procedures focused on detection of OD.Search for asymptomatic organ damage, cardiovascular disease, and chronic kidney disease.
Recommendation s Clas sa Levelb
Heart
An ECG is recommended in all h ypertensive patients to detect LVH,  left atrial dilatation, arrhythmias, or concomitant 
heart disease.
I B
In all patients with a history or physical examination suggestive of major arrhythmias, long-term ECG monitoring,  and, 
in case of suspected exer cise-induced arrhythmias,  a stress ECG test should be considered.
IIa C
suspected concomitant heart disease, when these are suspected.
IIa B
Whenever history suggests myocardial ischaemia, a stress ECG test is recommended, and, if positive or ambiguous, an  
imaging stress test (stress echocardiography, stress cardiac magnetic resonance or nuclear scintigraphy) is recommended.
I C
Arteries
Ultrasound scanning of car otid arteries should be considered to detect vascular hypertrophy or asymptomatic  
atherosclerosis, particularly in the elderly.
IIa B
Carotid–femoral PWV should be considered to detect large artery stiffening. IIa B
Ankle–brachial index should be considered to detect PAD. IIa B
Kidney
Measurement of serum cr eatinine and estimation of GFR is recommended in all hypertensive patients .c I B
Assessment of urinar y protein is recommended in all h ypertensive patients by dipstick . I B
Assessment of microalbuminuria is r ecommended in spot urine and re lated to urinary creatinine excretion. I B
Fundoscopy
haemorrhages, exudates,  and papilloedema, which are associated with increased CV risk.
IIa C




In hypertensive patients with cognitive decline, brain magnetic r esonance imaging or computed tomography may be  
considered for detecting silent brain infar ctions,  lacunar infar ctions,  microbleeds, and white matter lesions.  
IIb C
CV, cardiovascular; ECG, electrocardiogram; GFR, glomerural ﬁltration rate; LVH, left ventricular hypertrophy; MRI, magnetic resonance
imaging; PAD, peripheral artery disease; PWV, pulse wave velocity.
aClass of recommendation.
bLevel of evidence.
cThe MDRD formula is currently recommended but new methods such as the CKD-EPI method aim to improve the accuracy of the
measurement.2.6. Searching for secondary forms of hypertension
All patients should undergo simple screening for secondary
forms of hypertension, based on clinical history, physical
examination and routine laboratory investigations (Tables 9,
10 and 13). A secondary form of hypertension can be
indicated by a severe elevation in BP, sudden onset or
worsening of hypertension, poor BP response to drug
therapy and OD disproportionate to the duration of
hypertension. If the basal work-up leads to the suspicion
for secondary, speciﬁc diagnostic procedures are necessary,
as outlined in Table 13. Diagnostics of secondary forms of
hypertension should preferably be performed in referral
centres.3. Treatment approach
3.1. When to initiate antihypertensive drug treatment
3.1.1. Grade 2 and 3 hypertension and high-risk grade 1
hypertension
Evidence favouring drug therapy in patients with marked BP
elevation or inhypertensive patients at high total CV risk appears
overwhelming. BP represents a considerable component of
overall risk in these patients and so merits prompt intervention.
3.1.2. Low-to-moderate risk, grade 1 hypertension
The evidence favouring drug treatment in these individuals
is scant because no trial has speciﬁcally addressed this
Table 13 – Clinical indications and diagnostics of secondary hypertension.











Renal parenchymal disease History of urinary tract
infection or obstruction,
haematuria, analgesic
abuse; family history of
polycystic kidney disease.





in the urine, decreased
GFR.
Renal ultrasound Detailed work-up for kidney
disease.









Abdominal bruit Difference of >1.5 cm in
length between the two
kidneys (renal ultrasound),
rapid deterioration in renal
function (spontaneous or









Primary aldosteronism Muscle weakness; family




















































face, buffalo hump, red
striae, hirsutism).
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limited to patients strictly responding to grade 1 low risk
criteria ﬁnds a trend towards reduction of stroke with active
therapy. Further argument in favour of treating even low-
moderate risk grade 1 hypertensives is that waiting increases
total risk, and high risk is often not entirely reversible by
treatment. There is, however, no evidence for treating elderly
patients with grade 1 hypertension.
3.1.3. High normal blood pressure
The 2009 re-appraisal document pointed out that evidence in
favour of this early intervention was scanty. In two studies in
pre-diabetic or metabolic syndrome patients with a baseline
BP in the high normal range, administration of ramipril or
valsartan was not associated with any signiﬁcant improve-
ment in morbid and fatal CV events, compared with placebo.
Of two trials showing CV event reduction by lowering of BP in
patients with a previous stroke, one included only 16%
normotensives, while, in a sub-analysis of the other, signiﬁ-
cant beneﬁts were restricted to patients with baseline SBP
≥140 mmHg (most already under baseline antihypertensive
therapy). A review of placebo-controlled trials of antihyper-
tensive therapy in coronary patients showed dissimilar results
in different studies. Two studies have shown that a few years'
administration of antihypertensive agents to individuals with
high normal BP can delay transition to hypertension, but how
far the beneﬁt of this early intervention lasts—and whether it
can also delay events and be cost-effective—remains to be
proven.
Recommendations on initiation of antihypertensive drug
treatment are summarized in Fig. 2 and the summary table
below.Initiation of antihypertensive drug treatment.
Recommendations
Prompt initiation of drug t reatment is  recommended in individuals with grade  
CV risk, a few  weeks after or simultaneous ly with initiation of lifestyle changes.
Lowering BP with drugs is also recommended when total CV risk is high becau 
even when hypertension is in the grade 1 rang e.
Initiation of antihypertensive drug treatment should also be conside red in grad 
moderate risk, when BP is within this range at s everal  repeated visits or elevate 
remains within this range despite a  reasonable period of time with li festyle mea
In elder ly  hypertensive patients drug treatment is  recommended when SBP is  ≥
Antihypertensive drug treatment m ay also be considered in the elder ly (at leas
SBP is in the 140–159 mmHg rang e, provided that anti hypertensive treatment i 
Unless the necessary  evidence is obtained it is not  recommended to initiate an 
high normal BP.
Lack of evidence does also not allow recommending to initiate antihypertensiv
isolated elevation of brachial SBP, but these individuals should be followed clos
BP, blood pressure; CKD, chronic kidney disease; CV, cardiovascular; C
pressure.
aClass of recommendation.
bLevel of evidence.3.2. Blood pressure treatment targets
3.2.1. Recommendations of previous guidelines
The 2007 ESH/ESC Guidelines, in common with other guide-
lines, recommended two distinct BP targets, namely <140/90
in low-moderate risk hypertensives and <130/80 mmHg in
high-risk hypertensives (with diabetes, cerebrovascular, CV, or
renal disease). A careful review of the available evidence,
however, leads to a re-appraisal of some of these recommen-
dations, as detailed below.
3.2.2. Hypertension in the elderly
In the large number of randomized trials of antihypertensive
treatment in the elderly (including one in hypertensive
patients aged 80 years or more) all showing reduction in CV
events through lowering of BP, the average achieved SBP never
attained values <140 mmHg.
3.2.3. Diabetes mellitus
Lowering BP was found to be associated with important
reductions in CV events in patients with diabetes. The beneﬁcial
effect was seen from DBP reductions to between 80 and
85 mmHg. Action to Control Cardiovascular Risk in Diabetes
(ACCORD) study was unable to ﬁnd a signiﬁcant reduction in
incidence of major CV events in patients with diabetes whose
SBP was lowered to an average of 119 mmHg, compared with
patients whose SBP remained at an average of 133 mmHg.
3.2.4. Previous cardiovascular events
In two studies of patients who had experienced previous
cerebrovascular events, more aggressive lowering of BP,
although associated with signiﬁcant reductions in stroke
and CV events, did not achieve average SBP values lower than
130 mmHg; a third, much larger, study was unable to ﬁnd
outcome differences between groups achieving SBP of 136 vs.Classa Levelb
2 and 3 hypertension with a ny level of 
I A
se of OD, diabetes, CVD or CKD, 
I B
e 1 hypertensi ve patients at l ow to 
d by ambulato ry BP criteria , and 
su res.
IIa B
160 mmHg. I A
t when  younger than 80  years) when 
s well tolerated.
IIb C
tihypertensi ve drug ther apy at 
III A
e drug therapy in young individuals with
ely with lifestyle recommendations. III A
VD, cardiovascular disease; OD, organ damage; SBP, systolic blood
Fig. 2 – Initiation of lifestyle changes and antihypertensive drug treatment. Targets of treatment are also indicated. Colours
are as in Fig. 1. Consult Section 6.6 for evidence that, in patients with diabetes, the optimal DBP target is between 80 and
85 mmHg. In the high normal BP range, drug treatment should be considered in the presence of a raised out-of-office BP
(masked hypertension). Consult Section 4.2.4 for lack of evidence in favour of drug treatment in young individuals with
isolated systolic hypertension. BP, blood pressure; CKD, chronic kidney disease; CV, cardiovascular; CVD, cardiovascular
disease; DBP, diastolic blood pressure; HT, hypertension; OD, organ damage; RF, risk factor; SBP, systolic blood pressure.
Table 14 – Compelling and possible contra-indications to the use of antihypertensive drugs.
Drug Compelling Possible






A-V block (grade 2 or 3)
Metabolic syndrome
Glucose intolerance
Athletes and physically active patients
Chronic obstructive pulmonary disease













Bilateral renal artery stenosis





Bilateral renal artery stenosis
Women with child bearing potential
Mineralocorticoid receptor
antagonists
Acute or severe renal failure (eGFR
<30 mL/min)
Hyperkalaemia
A-V, atrio-ventricular; eGFR, estimated glomerular ﬁltration rate; LV, left ventricular.
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Table 15 – Drugs to be preferred in specific conditions.
Condition Drug
Asymptomatic organ damage
LVH ACE inhibitor, calcium antagonist, ARB
Asymptomatic atherosclerosis Calcium antagonist, ACE inhibitor
Microalbuminuria ACE inhibitor, ARB
Renal dysfunction ACE inhibitor, ARB
Clinical CV event
Previous stroke Any agent effectively lowering BP
Previous myocardial infarction BB, ACE inhibitor, ARB
Angina pectoris BB, calcium antagonist
Heart failure Diuretic, BB, ACE inhibitor, ARB, mineralocorticoid receptor antagonists
Aortic aneurysm BB
Atrial ﬁbrillation, prevention Consider ARB, ACE inhibitor, BB or mineralocorticoid receptor antagonist
Atrial ﬁbrillation, ventricular rate control BB, non-dihydropyridine calcium antagonist
ESRD/proteinuria ACE inhibitor, ARB
Peripheral artery disease ACE inhibitor, calcium antagonist
Other
ISH (elderly) Diuretic, calcium antagonist
Metabolic syndrome ACE inhibitor, ARB, calcium antagonist
Diabetes mellitus ACE inhibitor, ARB
Pregnancy Methyldopa, BB, calcium antagonist
Blacks Diuretic, calcium antagonist
ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker; BB, beta-blocker; BP, blood pressure; CV, cardiovascular; ESRD, end-
stage renal disease; ISH, isolated systolic hypertension; LVH, left ventricular hypertrophy.
c o r e t v a s a 5 6 ( 2 0 1 4 ) e 4 9 4 – e 5 1 8 e507140 mmHg. Among several trials in patients who had previous
coronary events, SBP values lower than 130 mmHg were
achieved by more intensive treatment in ﬁve trials, but with
inconsistent results.
3.2.5. Renal disease
In patients with CKD—with or without diabetes—there are two
treatment objectives: prevention of CV events (the most
frequent complication of CKD) and prevention or retardation
of further renal deterioration or failure. Unfortunately, evidence
concerning the BP target to be achieved in these patients isBlood pressure goals in hypertensive patients.
Recommendations
A SBP goal <140 mmHg : 
a) is recommended in patients at l ow–moderate CV risk;
b) is recommended in patients with diabetes;
c) should be considered in patients with previous stroke or TIA;
d) should be considered in patients with CHD;
e) should be considered in patients with diabetic or non-diabetic CKD
In elderly  hypertensives less than 80 years old with SBP ≥160 mmHg the r
SBP to between 150 and 140 mmHg . 
population SBP goals should be ad apted to individual tolerability.
In individuals older than 80 years and with initial SBP ≥160 mmHg , it is re
150 and 140 mmHg p rovided they are in good p hysical and mental condit
A DBP target of <90 mmHg is a lways recommended , except in patients w
are  recommended . It should nevertheless be considered that DBP values 
tolerated.
CHD, coronary heart disease; CKD, chronic kidney disease; CV, cardiovasc
transient ischaemic attack.
aClass of recommendation.
bLevel of evidence.scanty and confused by the uncertainty about the respective
roles of reduction of BP and speciﬁc effects of RAS blockers.
3.2.6. Clinic vs. home and ambulatory blood pressure targets
No direct evidence from randomized outcome studies is yet
available about BP targets when home or ambulatory BP
measurements are used. Out-of-ofﬁce measurements should
always be evaluated together with measurements at the clinic.
Notably, however, the adjustment of antihypertensive therapy
on the basis of a similar target ambulatory or home BP led to less-






e is solid evidence to  recommend  reducing 
I A
IIb C
commended to  reduce SBP to bet ween 
ions.
I B
ith diabetes , in whom values <85 mmHg 
between 80 and 85 mmHg a re sa fe and  well I A
ular; DBP, diastolic blood pressure; SBP, systolic blood pressure; TIA,
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4.1. Lifestyle changes
The lifestyle change measures, recommended in all patients
with hypertension to reduce BP and/or the number of CV risk
factors, are shown in the summary table below.Adoption of lifestyle changes.
Recommendations Classa Levelb,c Levelb,d
Salt  restriction to
5–6 g per day is
recommended. I A B
Moderation of
alcohol consumption
to no more than
20–30 g of ethanol
per day in men and
to no more than
10–20 g of ethanol











to BMI of  25 kg/m2 
and of waist
circumference to
<102 cm in men and





Regular exercis e, i.e.
at least 30 min of
moderate dynamic
exercise on 5 to 7
days per week is
recommended.
I A B
It is  recommended
to give all smo kers
advice to quit
smoking and to offer
assistance.
I A B
BMI, body mass index.
aClass of recommendation.
bLevel of evidence.
cBased on the effect on BP and/or CV risk proﬁle.
dBased on outcome studies.4.2. Pharmacological therapy
4.2.1. Choice of antihypertensive drugs
The largest meta-analyses available do not show clinically
relevant differences between drug classes. Therefore the
current guidelines reconﬁrm that diuretics (including thia-
zides, chlorthalidone and indapamide), beta-blockers, calcium
antagonists, ACE inhibitors and ARBs are all suitable for the
initiation and maintenance of antihypertensive treatment,
either as monotherapy or in some combinations. Other
antihypertensive agents, centrally active drugs and alpha-
receptor blockers, are also effective antihypertensive agents;
they are most often used in multiple drug combinations.
Once it is agreed that the major mechanism of the beneﬁts
of antihypertensive therapy is lowering of BP per se, the
effects on cause-speciﬁc outcomes of the various agents are
similar or differ by only a minor degree, the type of outcome in
a given patient is unpredictable, and all classes of antihyper-
tensive agents have their advantages but also contra-
indications (Tables 14 and 15).
4.2.2. Monotherapy and combination therapy
The obvious advantage of initiating treatment with monother-
apy is that of using a single agent, thus being able to ascribe
effectiveness and adverse effects to that agent. The disad-
vantage is that, when monotherapy is insufﬁciently effective,
ﬁnding an alternative monotherapy may be a painstaking
process and discourage adherence. Additionally, a meta-
analysis of more than 40 studies has shown that combining
two agents from any two classes of antihypertensive drugs
increases the BP reduction much more than increasing the
dose of one agent.
The advantage of initiating with combination therapy is a
prompter response (potentially beneﬁcial in high-risk
patients), a greater probability of achieving the target BP in
patients with higher BP values, and a lower probability of
discouraging patient adherence with many treatment
changes. Indeed, a recent survey has shown that patients
receiving combination therapy have a lower drop-out rate
than patients given any monotherapy. A further advantage is
that there are physiological and pharmacological synergies
between different classes of agents, that may not only justify a
greater BP reduction but also cause fewer side-effects and
may provide larger beneﬁts than those offered by a single
agent.
The use of combinations of two antihypertensive drugs at
ﬁxed doses in a single tablet is encouraged, because reducing
the number of pills to be taken daily improves adherence,
which is unfortunately low in hypertension, and increases the
rate of BP control.
Fig. 4 – Possible combinations of classes of antihypertensive drugs. Green continuous lines: preferred combinations; green
dashed line: useful combination (with some limitations); black dashed lines: possible but less well-tested combinations; red
continuous line: not recommended combination. Although verapamil and diltiazem are sometimes used with a beta-blocker
to improve ventricular rate control in permanent atrial fibrillation, only dihydropyridine calcium antagonists should
normally be combined with beta-blockers. ACE, angiotensin converting enzyme.
Fig. 3 – Monotherapy vs. drug combination strategies to achieve target BP. Moving from a less intensive to a more intensive
therapeutic strategy should be done whenever BP target is not achieved. BP, blood pressure; CV, cardiovascular.
c o r e t v a s a 5 6 ( 2 0 1 4 ) e 4 9 4 – e 5 1 8 e509
c o r e t v a s a 5 6 ( 2 0 1 4 ) e 4 9 4 – e 5 1 8e510On the whole the suggestion, given in the 2007 ESH/ESC
Guidelines, of considering initiation with a drug combination
in patients at high risk or with markedly high baseline BP can
be reconﬁrmed (see Figs. 3 and 4, Table 16 and the summary




indapamide) , beta-bloc kers,
calcium antagonists,  ACE
inhibitors, and angiotensin
receptor blockers are all
suitable and  recommended
for the initiation and
maintenance of
antihypertensi ve treatment , 
either as monotherapy or in
some combinations with
each other. 




because used in trials
in those conditions or because
of greater effectiveness in
specific types of OD.
I A
IIa C
Initiation of anti hypertensi ve
therapy with a two-drug
combination m ay be
considered in patients with
marked ly high baseline BP or
at high CV risk. 
IIb C
The combination of t wo
antagonists of the




should be considered and
probably are beneficial in
proportion to the extent of
BP reduction. However,
combinations that h ave been





fixed doses in a single tablet
may be recommended and
favoured, because reducing
the number of daily pills
improves adhe rence, which is
low in patients with
hypertension.
IIb B
ACE, angiotensin-converting enzyme; BP, blood pressure; CV,
cardiovascular; OD, organ damage; RAS, renin–angiotensin system.
aClass of recommendation.
bLevel of evidence.5. Treatment strategies in special conditions
5.1. White-coat hypertension
No randomized trial has ever been performed speciﬁcally in
subjects with WCH to investigate whether administration of
BP-lowering drugs leads to a reduction in CV morbid and fatal
events. On the other hand, WCH was presumably well
represented in antihypertensive drug trials. Drug therapy
may be considered in addition to appropriate lifestyle changes,
especially when additional risk factors are present or when
there is disagreement between home and ambulatory BP
values.
5.2. Masked hypertension
Isolated ambulatory or masked hypertension is infrequently
diagnosed because ﬁnding a normal clinic BP exceptionally
leads to home or ambulatory BP measurements. When this
condition is identiﬁed, however, both lifestyle measures and
antihypertensive drug treatment should be considered.Treatment strategies in white-coat and masked hyper-
tension.
Recommendations Classa Levelb
In white-coat hype rtensives without additional 
risk factors, ther apeutic intervention should be 
conside red to be limited to li festyle changes 
only, but this decision should be accompanied  by 
a close follow-up.
IIa C
In white-coat hype rtensives with a higher CV 
risk because of metabolic derangements or 
asymptomatic OD, drug treatment m ay be
conside red in a ddition to li festyle changes.  
IIb C
In masked hypertension , both lifestyle measu res 
and antihypertensi ve drug t reatment should be 
conside red , because this type of hypertension 
has been consistently  found to h ave a CV 
hypertension.
IIa C
CV, cardiovascular; OD, organ damage.
aClass of recommendation.
bLevel of evidence5.3. Elderly
There is a strong evidence of beneﬁts from lowering of BP by
antihypertensive treatment in the elderly individuals with
initial SBP of ≥160 mmHg, whose SBP was reduced to values
<150. However, at least in elderly individuals younger than 80
years, antihypertensive treatment may be considered at
initial SBP values >140 mmHg. There is evidence in favour of
diuretics, beta-blockers, calcium antagonists, ACE inhibitors,
and ARBs.
Antihypertensive treatment strategies in the elderly.
Recommendations Classa Levelb
In elderly  hypertensives with
SBP ≥160 mmHg the re is solid
evidence to recommend  reducing
SBP to between 150 and 140
mmHg.
I A
In fit elderly patients <80 years
old antihypertensive treatment
may be considered at SBP values
≥140 mmHg with a target
SBP <140 mmHg if t reatment is
well tolerated. 
IIb C
In individuals older than 80 years
with an initial SBP ≥160 mmHg it
is recommended to  reduce SBP
to between 150 and 140 mmHg,
provided they are in good
physical and mental conditions.
I B
In frail elderly patients, it is
recommended to le ave decisions
on antihypertensive therapy to
the treating physician,  and based
on monitoring of the clinical








All hype rtensi ve agents  are
recommended  and  can  be  used  in
the elder ly, although  diu retics  an d
calcium anta gonists  may be
preferred  in  isolated  systoli c
hype rtension. 
I A
SBP, systolic blood pressure.
aClass of recommendation.
bLevel of evidence.
Treatment strategies in hypertensive women.
Recommendations Classa Levelb
Hormone therapy and selecti ve
oestrogen  receptor modulators
are not  recommended and
should not be used  for prima ry
or secondary prevention of CV D.
If treatment of  younger
perimenopausal women is
conside red  for severe menopausal
symptoms, the benefits should be
weighed against potential risks.
III A
Drug treatment of s evere
hypertension in p regnancy
(SBP >160 mmHg or
DBP >110 mmHg) is
recommended.
I C
Drug treatment m ay also be
conside red in p regnant  women
with persistent elevation of BP
≥150/95 mmHg, and in those with
BP ≥140/90 mmHg in the
presence of gestational
hypertension , subclinical OD or
symptoms.
IIb C
In women at high risk of
pre-eclampsia , provided th ey are
at low risk of gast rointestinal
haemo rrhage, treatment with
low dose aspirin f rom 12 weeks
until deli very may be conside red. 
IIb B
In women with child-bearing
potential RAS bloc kers a re not
recommended and should be
avoided.
III C
Methyldopa , labetolol  an d
nifedipine should be conside red
preferential  anti hype rtensi ve drug s
in pregnanc y. Intr avenou s
labetolol or  infusion  of
nitroprusside should b e
considered  in  case  of  emergenc y
(pre-eclampsia) .
IIa B
BP, blood pressure; CVD, cardiovascular disease; DBP, diastolic
blood pressure; OD, organ damage; RAS, renin–angiotensin system;
SBP, systolic blood pressure.
aClass of recommendation.
bLevel of evidence.
c o r e t v a s a 5 6 ( 2 0 1 4 ) e 4 9 4 – e 5 1 8 e5115.4. Young adults
In young adults with moderately high BP it is almost
impossible to provide recommendations based on evidence
from intervention trials since outcomes are delayed. Antihy-
pertensive treatment may be considered, and BP should be
reduced to <140/90 mmHg. The case may be different for
young individuals with elevated SBP but normal DBP values;
these subjects sometimes have normal central SBP and they
can be followed with lifestyle measures only.
5.5. Women
There is no evidence for any antihypertensive agent that there
would be different efﬁcacy in males and females. In women
with child-bearing potential, ACE inhibitors and ARBs should
be avoided.
Use of oral contraceptives is associated with small
increases in BP; about 5% of users develop hypertension.
Hormone replacement therapy should not be used for primary
or secondary prevention of CVD; the probability that BP will
increase is, however, low.In pregnancy, drug treatment of severe hypertension
(SBP > 160 or DBP > 110 mmHg) is required. The beneﬁts of
antihypertensive therapy for mildly to moderately elevated BP
are uncertain.
The recommendations to use methyldopa, labetalol and
nifedipine in pregnancy can be conﬁrmed. Beta-blockers
(possibly causing foetal growth retardation if given in early
pregnancy) and diuretics (in pre-existing reduction of plasma
volume) should be used with caution. All agents interfering
with the RAS should be avoided. In emergency (pre-eclamp-
sia), intravenous labetalol is the drug of choice with sodium
nitroprusside or nitroglycerin in intravenous infusion being
the other option.
Treatment strategies in hypertensive patients with me-
tabolic syndrome.
Recommendations Classa Levelb
Lifestyle changes , particular ly
weight loss and p hysical e xercise,
are to be  recommended to all
individuals with the metabolic
syndrom e. These inte rventions
improve not on ly B P, but the
I B
c o r e t v a s a 5 6 ( 2 0 1 4 ) e 4 9 4 – e 5 1 8e5125.6. Diabetes mellitus
There is no clear evidence of beneﬁts from initiating
antihypertensive drug treatment at SBP levels <140 mmHg
(high normal BP), nor there is evidence of beneﬁts from aiming
at targets <130 mmHg. Treatment is strongly recommended in
diabetic patients when SBP is ≥140 mmHg. DBP target is
between 80 and 85 mmHg. How far below 140 mmHg the SBP
target should be in patients with diabetes is not clear.
Supportive evidence against lowering SBP <130 mmHg comes
from the ACCORD trial. All classes of antihypertensive agents
are useful. ACE inhibitor or an ARB is recommended. However,
the simultaneous administration of two RAS blockers should
be avoided. Thiazide and thiazide-like diuretics are often used
together with RAS blockers. Calcium antagonists are useful
especially when combined with an RAS blocker. Beta-blockers
are useful in combination therapy, especially in patients with
CHD and heart failure.Treatment strategies in patients with diabetes.
Recommendations Classa Levelb
While initiation of
antihypertensi ve drug treatment
in diabetic patients whose SBP
is ≥160 mmHg is mandato ry, it is
strongly  recommended to sta rt
drug treatment also when SBP is
≥140 mmHg.
I A
A SBP goal <140 mmHg is
recommended in patients with
diabetes.
I A
The DBP target in patients with
diabetes is  recommended to be
<85 mmHg.
I A
All classes of anti hypertensi ve
agents are  recommended and can
be used in patients with diabetes;
RAS blockers may be preferred,
especially in the presence of
protei nuria or microalbumi nuria.  
I A
It is recommended that individual




two blockers of the RAS is not
recommended and should be
avoided in patients with diabetes. 
III B
DBP, diastolic blood pressure; RAS, renin–angiotensin system; SBP,
systolic blood pressure.
aClass of recommendation.
bLevel of evidence.5.7. Metabolic syndrome
As the metabolic syndrome can often be considered as a 'pre-
diabetic' state, agents such as RAS blockers and calcium
antagonists are preferred, while beta-blockers and diuretics
should only be considered as additional drugs, preferably at
low doses.metabolic components of the
syndrome and del ay diabetes
onset.  
As the metabolic syndrome can
be considered a  ‘p re-diabetic’
state, antihypertensi ve agents
potentially imp roving or at least
not worsening insulin sensitivit y,
such as RAS blockers and calcium
antagonists , should be considered
as the preferred drugs.
Beta-blockers (with the exception
of vasodilating beta-blockers) and
diuretics should be conside red on ly




It is  recommended  to  prescrib e
antihype rtensi ve drugs wit h
particular ca re in  hype rtensi ve
patients with metabolic
disturbances when  BP  is  ≥140/90
mmHg after  a suitable  period  of
lifestyle  changes , and  to  maintai n
BP < 140 /90 mmHg.
I B
BP lowering drugs a re not
recommended in individuals with
metabolic syndrome and
high normal B P.
III A
BP, blood pressure; RAS, renin–angiotensin system.
aClass of recommendation.
bLevel of evidence.5.8. Obstructive sleep apnoea
The association between obstructive sleep apnoea and
hypertension is well documented. It has been shown in
Table 16 – Major drug combinations used in trials of antihypertensive treatment in a step-up approach or as a randomized
combination.
Trial Comparator Type of patients SBP diff (mmHg) Outcomes
ACE-I and diuretic combination
PROGRESS Placebo Previous stroke or TIA 9 28% strokes (P < 0.001)
ADVANCE Placebo Diabetes 5.6 9% micro/macro vascular
events (P = 0.04)
HYVET Placebo Hypertensives aged ≥80 years 15 34% CV events (P < 0.001)
CAPPP BB + D Hypertensives +3 +5% CV events (P = NS)
Angiotensin receptor blocker and diuretic combination
SCOPE D + placebo Hypertensives aged ≥70 years 3.2 28% non fatal strokes (P = 0.04)
LIFE BB + D Hypertensives with LVH 1 26% stroke (P < 0.001)
Calcium antagonist and diuretic combination
FEVER D + placebo Hypertensives 4 27% CV events (P < 0.001)
ELSA BB + D Hypertensives 0 NS difference in CV events
CONVINCE BB + D Hypertensives with risk factors 0 NS difference in CV events
VALUE ARB + D High-risk hypertensives 2.2 3% CV events (P = NS)
ACE-I and calcium antagonist combination
SystEur Placebo Elderly with ISH 10 31% CV events (P < 0.001)
SystChina Placebo Elderly with ISH 9 37% CV events (P < 0.004)
NORDIL BB + D Hypertensives +3 NS difference in CV events
INVEST BB + D Hypertensives with CHD 0 NS difference in CV events
ASCOT BB + D Hypertensives with risk factors 3 16% CV events (P < 0.001)
ACCOMPLISH ACE-I + D Hypertensives with risk factors 1 21% CV events (P < 0.001)
BB and diuretic combination
Coope and Warrender Placebo Elderly hypertensives 18 42% strokes (P < 0.03)
SHEP Placebo Elderly with ISH 13 36% strokes (P < 0.001)
STOP Placebo Elderly hypertensives 23 40% CV events (P = 0.003)
STOP 2 ACE-I or CA Hypertensives 0 NS difference in CV events
CAPPP ACE-I + D Hypertensives 3 5% CV events (P = NS)
LIFE ARB + D Hypertensives with LVH +1 +26% stroke (P < 0.001)
ALLHAT ACE-I + BB Hypertensives with risk factors 2 NS difference in CV events
ALLHAT CA + BB Hypertensives with risk factors 1 NS difference in CV events
CONVINCE CA + D Hypertensives with risk factors 0 NS difference in CV events
NORDIL ACE-I + CA Hypertensives 3 NS difference in CV events
INVEST ACE-I + CA Hypertensives with CHD 0 NS difference in CV events
ASCOT ACE-I + CA Hypertensives with risk factors +3 +16% CV events (P < 0.001)
Combination of two renin–angiotensin–system blockers/ACE-I + ARB or RAS blocker + renin inhibitor
ONTARGET ACE-I or ARB High-risk patients 3 More renal events
ALTITUDE ACE-I or ARB High-risk patients 1.3 More renal events
ACE-I, angiotensin-converting-enzyme inhibitor; ARB, angiotensin receptor blocker; BB, beta-blocker; CA, calcium antagonist; CHD, coronary
heart disease; CV, cardiovascular; D, diuretic; ISH, isolated systolic hypertension; LVH, left ventricular hypertrophy; NS, not signiﬁcant; RAS,
renin–angiotensin system; TIA, transient ischaemic attack.
c o r e t v a s a 5 6 ( 2 0 1 4 ) e 4 9 4 – e 5 1 8 e513several analyses, however, that the effect of prolonged positive
airway pressure therapy on BP is very small. Well-designed
therapeutic studies are too few.
5.9. Diabetic and non-diabetic nephropathy
In observational studies, the relationship between BP and
progression of CKD and incident ESRD is direct and
progressive. SBP should be lowered to <140 mmHg and when
overt proteinuria is present values <130 mmHg may be
pursued.Reduction of proteinuria is widely considered as a
therapeutic target. Several RCTs have clearly indicated that
RAS blockade is more effective. Achieving BP targets usually
requires combination therapy. Mineralocorticoid receptor
antagonists cannot be recommended in CKD. Loop diuretics
should replace thiazides if serum creatinine is 1.5 mg/dL or
eGFR is <30 mL/min/1.73 m2.
In chronic kidney disease stage 5D, hypertension is a
ubiquitous ﬁnding in haemodialysis patients and has major
implications for survival. Randomized controlled trials are rare
in haemodialysis and should be encouraged.
Therapeutic strategies in hypertensive patients with
nephropathy.
Recommendations Classa Levelb
Lowering SBP to <140 mmHg
should be considered.
IIa B
When overt proteinuria is
present , SBP values <130 mmHg
may be conside red , provided that
changes in eGFR are monito red.
IIb B
RAS bloc kers  are mo re ef fecti ve
in reducing albumi nuria than othe r
antihype rtensi ve agents , and are
indicated in  hype rtensi ve patient s
in the  presence  of
microalbumi nuria  or  overt
protei nuria. 
I A
Reaching BP goals usual ly  requi res
combination ther apy, and it is
recommended to combine
RAS blockers with other
antihype rtensi ve agents.
I A
Combination of  two RA S
blockers , though potentially mo re
effecti ve in  reducing  protei nuria , is
not recommended .
III A
Aldoste rone anta gonists cannot
be recommended in CK D,
especially in combination with a
RAS blocker, because of
the risk of excessive  reduction in
renal function and of
hyperkalaemia. 
III C
BP, blood pressure; CKD, chronic kidney disease; eGFR, estimated




c o r e t v a s a 5 6 ( 2 0 1 4 ) e 4 9 4 – e 5 1 8e5145.10. Cerebrovascular diseaseTherapeutic strategies in hypertensive patients with
cerebrovascular disease.
Recommendations Classa Levelb
It is not recommended to
intervene with BP-lowering
therapy during the first week after
acute stroke irrespective of BP
level , although clinical judgemen t
should be  used  in  the  face  of  very
high SBP  values .
III B
Antihype rtensi ve treatment  is
recommended  in  hype rtensi ve
patients with  a histo ry of  st roke
or TIA , even  when  initial SBP  is  in
the 140–15 9 mmHg rang e. 
I B
In hypertensive patients with a
history of stroke or TIA, a SBP
goal of <140 mmHg should be
considered.
IIa B
In elderly  hypertensives with
previous stroke or TIA, SBP
values for inte rvention and goal
may be considered to be
somewhat highe r. 
IIb B
All drug regimens are
recommended for st roke
prevention, provided that BP is
effectively  reduced.
I A




Therapeutic strategies in hypertensive patients with
heart disease.
Recommendations Classa Levelb
In hypertensi ve patients with
CHD, a SBP goal <140 mmHg
should be conside red.
IIa B
In hypertensi ve patients with a
recent  myocardial infarction
beta-blockers a re  recommended.
In case of other CHD all 
antihypertensi ve agents can be
used, but beta-blockers and
calcium antagonists are to be
preferred , for symptomatic
reasons (angina).
I A
Diuretics , beta-blockers , ACE
inhibitors, angiotensin  recepto r
blockers , and/or mineralocorticoi d
receptor anta gonists a re
recommended in patients wit h
heart failure or severe LV
dysfunction to reduce mortality
and hospitalization .
I A
In patients with hea rt failu re and
prese rved EF , there is no  evidence
that antihypertensi ve ther apy per
se or any particular drug, is
beneficial. However, in these
patients, as well as in patients
with hypertension and systolic
dysfunction, lowering SBP to
around 140 mmHg should be
considered . Treatment guided  by
relief of symptoms (congestion
with diuretics , high heart rate
with beta-bloc kers , etc.) should
also be conside red.
IIa C
ACE inhibitors  and  angiotensi n
receptor bloc kers (an d
beta-blockers an d
mineralocorticoid  recepto r
antagonists if hea rt
failure coexists) should be
considered as antihypertensive
agents in patients at risk of new
or recurrent atrial fibrillation. 
IIa C
It is recommended that all
c o r e t v a s a 5 6 ( 2 0 1 4 ) e 4 9 4 – e 5 1 8 e5155.11. Heart disease
5.11.1. Coronary heart disease
RCTs of antihypertensive treatment do not provide consistent
evidence that SBP target should be <130 mmHg in hyperten-
sive patients with overt CHD, nor is there consistent evidence
that antihypertensive treatment should be initiated with high
normal BP.
There is evidence for greater beneﬁts from beta-blockers
after a recent myocardial infarction, a condition in which ACE
inhibitors have also been successfully tested. Beta-blockers
and calcium antagonists are to be preferred in cases of angina.
5.11.2. Heart failure
Preventing heart failure in hypertensive patients is the largest
beneﬁt associated with BP-lowering drugs.
Hypertension is common in heart failure patients with
preserved LV ejection fraction; no RCT, however, has been
carried out to test the effects of reducing BP in these patients.
5.11.3. Atrial ﬁbrillation
Hypertensive patients with atrial ﬁbrillation should receive
oral anticoagulation therapy. Newer drugs, either direct
thrombin inhibitors (dabigatran) or factor Xa inhibitors
(rivaroxaban, apixaban) have been shown to be non-inferior
and sometimes superior to warfarin. Most patients show a
high ventricular rate when in atrial ﬁbrillation; beta-blockers
and non-dihydropyridine calcium antagonists are hence
recommended. ACE inhibitors or ARBs should be considered
in patients at risk of recurrent paroxysmal atrial ﬁbrillation.
5.11.4. Left ventricular hypertrophy
LVH reduction is closely related to BP reduction. For similar BP
reductions, however, ARBs, ACE inhibitors and calcium
antagonists have been found to be more effective than beta-
blockers.patients with LVH recei ve
antihypertensi ve agents.
I B
In patients with  LVH, initiation of
treatment  with one of  the agent s
that have sh own  a greater  abilit y
to reg ress  LVH should  be
considered, i. e. ACE inhibitors ,
angiotensin receptor bloc kers an d
calcium antagonists .
IIa B
ACE, angiotensin-converting enzyme; CHD, coronary heart disease;
EF, ejection fraction; LV, left ventricle; LVH, left ventricular
hypertrophy; SBP, systolic blood pressure.
aClass of recommendation.
bLevel of evidence.
c o r e t v a s a 5 6 ( 2 0 1 4 ) e 4 9 4 – e 5 1 8e5165.12. Atherosclerosis, arteriosclerosis, and peripheral
artery diseaseTherapeutic strategies in hypertensive patients with
atherosclerosis, arteriosclerosis, and peripheral artery
disease.
Recommendations Classa Levelb
In the  presence  of  ca roti d
atheroscle rosis , prescription  of
calcium anta gonists  and  ACE
inhibitors should be  conside red  as
these agents have show n a greate r
efficacy in  delaying  athero sclero sis
progres sio n than di uretic s and
beta-blockers . 
IIa B
In hype rtensive patients with a
PWV above 10 m/s all
antihype rtensive drugs should be
considered provided that a BP
reduction to <140/90 mmHg is
consistently achi eved .  
IIa B
Antihype rtensive therapy is
recommended in  hype rtensi ve
patients with PAD to achieve a
goal of <140/90 mmHg,
because of their high risk of
myoca rdial infarction , stroke,
heart failure, and CV death. 
I A
Though a careful  follow up is
necessary, beta-bloc kers may be
considered for the treatment of
arterial hype rtension in
patients with PAD, since their use
does not appear to be associated
with exacerbation of PAD
symptoms. 
IIb A
ACE, angiotensin-converting enzyme; BP, blood pressure; CV,




Therapeutic strategies in patients with resistant hyper-
tension.
Recommendations Classa Levelb
In resistant  hype rtensi ve patient s
it is  recommended  that  physician s
check whether  the  drugs  include d
in the  existing  multiple  dru g
regimen  have any BP  lowerin g
effect , and  withdr aw them  if  thei r
effect  is  absent  or  minimal. 
I C
Mineralocorticoid  receptor
antagonists, amiloride, and the
alpha-1-blocker d oxazosin should
be considered , if no
contraindication exists. 
IIa B
In case of ineffectiveness of drug
treatment invasive procedures
such as renal denervation and
baroreceptor stimulation may be
considered.
IIb C
Until more evidence is available
on the long-term efficacy and
safety of renal denervation and
baroreceptor stimulation , it is
recommended that these
procedures remain in the hands
of experienced operators and
diagnosis and follow-up  restricted
to hypertension centers. 
It is recommended that the
invasive approaches are
considered only for truly resistant
hypertensive patients, with clinic
values ≥160 mmHg SBP or
≥110 mmHg DBP and with BP





ABPM, ambulatory blood pressure monitoring; BP, blood pressure;
DBP, diastolic blood pressure; SBP, systolic blood pressure.
aClass of recommendation.
bLevel of evidence.5.13. Sexual dysfunction
Sexual dysfunction is more prevalent in hypertensive than
normotensive individuals, but available information mostly
concerns men. Erectile dysfunction is considered to be an
independent CV risk factor. ARBs, ACE inhibitors, calcium
antagonists and vasodilating beta-blockers have neutral or
even beneﬁcial effects on erectile function. Phospho-dies-
terase-5 inhibitors may be safely administered to hyperten-
sives.
5.14. Resistant hypertension
Hypertension is deﬁned as resistant to treatment when a
therapeutic strategy that includes appropriate lifestyle mea-
sures plus a diuretic and two other antihypertensive drugs at
adequate doses fails to lower SBP and DBP values to <140 and
90 mmHg, respectively. The prevalence of resistant hyperten-
sion ranges from 5 to 30%. A frequent cause of spuriousresistant hypertension is failure to adhere to the prescribed
treatment regimen.
A good response has been reported to the use of
mineralocorticoid receptor antagonists, the alpha-1-blocker
doxazosin and a further increase in diuretic dose, loop diuretic
replacing thiazides or chlorthalidone if renal function is
impaired.
Patients with resistant hypertension should be monitored
closely. Ofﬁce BP should be measured at frequent intervals and
ambulatory BP at least once a year.
Chronic ﬁeld electrical stimulation of carotid sinus nerves
via implanted devices has recently been reported to reduce SBP
and DBP in resistant hypertensive individuals. However,
longer-term observations have involved only a restricted
number of patients.
A growing non-drug therapeutic approach to resistant
hypertension is bilateral destruction of the renal nerves by
radiofrequency ablation catheters. The procedure has been
shown to induce a marked reduction in ofﬁce BP which was
sustained after one year. At present, the renal denervation
method is promising, but in need of additional data.
Recommendations Classa Levelb
It is  recommended  to  use  stati n
therapy in  hype rtensi ve patient s
at moderate  to  high  CV  risk ,
targeting a low-densit y
lipoprotein choleste rol valu e
<3.0 mmol/L (115 mg/dL). 
I A
When overt CHD is present, it is
recommended to administer
statin therapy to achieve
low-density lipoprotein
cholesterol levels <1.8 mmol/L
(70 mg/dL). 
I A
Antiplatelet therapy, in particular
low-dose aspirin, is recommended
in hypertensive patients with
previous CV events.
I A
Aspirin should also be
considered in hypertensive
patients with reduced renal
function or a high CV risk,
provided that BP is well
controlled. 
IIa B
Aspirin is not recommended for
CV prevention in low-moderate
risk hypertensive patients, in
whom absolute benefit
and harm are equivalent.
III A
In hypertensive patients with
diabetes, a HbA1c  target of <7.0%
is recommended with antidiabetic
treatment. 
I B
In more fragile elderly patients
with a longer diabetes duration,
more comorbidities and at high
risk, treatment to a HbA1c target
of <7.5–8.0% should be
IIa C
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Hypertensive emergency is clinically deﬁned as the presence
of very high SBP or DBP (>180 mmHg or >120 mmHg,
respectively) associated with ischaemic OD (retina, kidney,
heart or brain). Current treatment is founded on agents that
can be administered by intravenous infusion and titrated.
5.16. Perioperative management of hypertension
Sudden withdrawal of clonidine or beta-blockers before
surgery should be avoided. Diuretics should not be given on
the day of surgery.
5.17. Renovascular hypertension
Renovascular artery stenosis secondary to atherosclerosis is
relatively frequent. It is still debated whether patients with
hypertension or renal insufﬁciency beneﬁt from interventions:
mostly percutaneous renal artery stenting. While there is
convincing information favouring this procedure in younger
(mostly female) patients with uncontrolled hypertension in
ﬁbromuscular hyperplasia, the matter is highly controversial
in atherosclerotic renovascular hypertension.
5.18. Primary aldosteronism
In documented unilateral primary aldosteronism, caused either
by aldosterone-producing adenoma or unilateral adrenal
hyperplasia, the treatment of choice is unilateral laparoscopic
adrenalectomy, whereas treatment with mineralocorticoid
receptor antagonists is indicated in patients with bilateral
adrenal disease. The lowest effective dose of spironolactone
should be found; the incidence of gynaecomasty with spir-
onolactone is dose-related.6. Treatment of associated risk factors
Treatment of risk factors associated with hypertension.considered. 
BP, blood pressure; CHD, coronary heart disease; CV, cardiovas-
cular; HbA1c, glycated haemoglobin.
aClass of recommendation.
bLevel of evidence.
Fig. 5 – Sensitivity to detect treatment-induced changes,
time to change and prognostic value of change by markers
of asymptomatic OD. ECG, electrocardiogram; echo,
echocardiogram; eGFR, estimated glomerular filtration rate;
LVH, left ventricular hypertrophy; OD, organ damage.
c o r e t v a s a 5 6 ( 2 0 1 4 ) e 4 9 4 – e 5 1 8e5187. Follow-up of hypertensive patients
After the initiation of antihypertensive drug therapy,
the patient should be seen at 2- to 4-week intervals to evaluate
the effects on BP and to assess possible side-effects. Once the
target is reached, a visit interval of 3–6 months is reasonable.
Many of the later visits may be performed by non-physician
health workers, such as nurses. For stable patients, HBPM and
electronic communication with the physician (SMS, e-mail,
social media, or automated telecommunication of home BP
readings) may also provide an acceptable alternative. It is
nevertheless advisable to assess risk factors and asymptom-
atic OD at least every 2 years (Fig. 5).
Individuals with high normal BP or white-coat hyperten-
sion, even if untreated, should be scheduled for regular follow-
up (at least annual visits) to measure ofﬁce and out-of-ofﬁce BP
as well as to check the CV risk proﬁle.
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